SCHEMBL6178465

SCHEMBL6178465

CC=C(C(=O)OC)c1ccc(OC)cc1Oc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 3/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HTT P42858 2/20 0.45
PKM P14618 1/20 0.45
AKR1C3 P42330 2/20 0.44
AKR1C2 P52895 2/20 0.44
PYGM P11217 1/20 0.44
PGR P06401 2/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
SLC6A2 P23975 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6932848 0.84 CTNNB1 (0.54) MEN1KMT2AKDM4EPOLBRAB9A
SCHEMBL7168343 0.80 KMT2A (0.56) MEN1KMT2AKDM4EPOLBNPC1
SCHEMBL9151216 0.77 MEN1 (0.46) MEN1KMT2AKDM4EPOLBRAB9A
SCHEMBL9151229 0.77 MEN1 (0.46) MEN1KMT2AKDM4EPOLBRAB9A
SCHEMBL2107594 0.74 KDM4E (0.59) MEN1KMT2AKDM4EPOLBNPC1
SCHEMBL2855939 0.74 KDM4E (0.59) MEN1KMT2AKDM4EPOLBNPC1
SCHEMBL29359491 0.74 KDM4E (0.52) MEN1KMT2AKDM4EPOLBNPC1
SCHEMBL202624 0.74 KDM4E (0.52) MEN1KMT2AKDM4EPOLBNPC1
SCHEMBL9150670 0.73 MEN1 (0.43) MEN1KMT2AKDM4EPOLBRAB9A
SCHEMBL9150680 0.73 MEN1 (0.43) MEN1KMT2AKDM4EPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1061921-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-03-30 EP disclosed
US-20020147334-A1 Vitronectin Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2002-10-10 US disclosed
EP-1061921-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-27 EP disclosed
WO-1999045927-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147334-A1 Vitronectin Receptor Antagonists ADGRF1, FN1, CALCR MEN1 720/4885KMT2A 4749/4885KDM4E 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.